Clinical Trials Logo

Muscle Weakness clinical trials

View clinical trials related to Muscle Weakness.

Filter by:

NCT ID: NCT02104102 Recruiting - Clinical trials for Muscle Weakness Conditions

Biomedical Instrumentation in the Study of Mirror Therapy in Elderly's Hands Motor Activity

Start date: January 2014
Phase: N/A
Study type: Interventional

Check if the Mirror therapy represents an effective method in improving the motor activity of the hands of institutionalized elderly.

NCT ID: NCT02102919 Completed - Muscle Weakness Clinical Trials

Innovative Training Program for Elderly in Need of Care Individuals

Start date: January 2013
Phase: Phase 4
Study type: Interventional

The goal of this randomized controlled study was to examine the effects of a 8 weeks innovative training regime (stochastic resonance whole-body vibration [SR-WBV] and virtual virtual games [VG]) in the skilling up phase on physical performance and strength in elderly in need of care population.

NCT ID: NCT02100969 Completed - Myasthenia Gravis Clinical Trials

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).

NCT ID: NCT02090725 Terminated - Muscle Weakness Clinical Trials

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

3-4DAP
Start date: February 2004
Phase: Phase 2
Study type: Interventional

The main purpose for this study is to provide access to 3,4 DAP, a drug which has demonstrated to be effective in treating weakness associated with Lambert-Eaton Myasthenic Syndrome. LEMS is a rare autoimmune cause of a defect in neuromuscular transmission. The disorder is clinically characterized by fluctuating muscle weakness, hyporeflexia and autonomic dysfunction.

NCT ID: NCT02080936 Completed - COPD Clinical Trials

Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD

M2W
Start date: January 2014
Phase: N/A
Study type: Observational

Peripheral muscle mass and strength are relevant indicators of COPD survival. Current guidelines recommend to assess muscle strength only in muscle wasted patients. However, a recent study reported quadriceps weakness without muscle wasting (Menon, M et al. Resp. Res.2012, 13:119). Thus, these guidelines raise the risk to miss out some weak patients. In clinical settings, fat-free-mass index (FFMI) is indicated as a simple index to assess muscle wasting. We aimed at determining the prevalence of patients entering in pulmonary rehabilitation (PR) a priori not eligible for muscle strength evaluation given the lack of muscle wasting clinical signs.

NCT ID: NCT02066519 Completed - Myasthenia Gravis Clinical Trials

Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis

MGEX
Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate that a 3 months physical exercise programme improves the Quality of Life of patients with generalized Myasthenia Gravis (MG) stabilized since at least 6 months under prednisone and/or azathioprine.

NCT ID: NCT02042937 Completed - Muscular Weakness Clinical Trials

Enhancing Gluteus Maximus Recruitment

Start date: January 2014
Phase: N/A
Study type: Interventional

Can participants enhance gluteus maximus recruitment during a single-leg squat test following a neuromuscular training program?

NCT ID: NCT02037516 Completed - Morbid Obesity Clinical Trials

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

Start date: January 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if residual weakness after weight loss surgery leads to an increased risk of respiratory complications in the postoperative period.

NCT ID: NCT02033057 Recruiting - Polyneuropathy Clinical Trials

Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.

Start date: October 2012
Phase: Phase 4
Study type: Interventional

Even 20-50% of patients under sedation and mechanical ventilation develops myopathy and / or neuropathy which difficulties both the process of extubation and the functional recovery. The objective of this project is to analyze the effect of muscle electrostimulation (ESM) on muscle weakness acquired in Intensive Care Unit (ICU) and its consequences. Study design: a single center, prospective, randomized trial to be held in the ICU of " Universitarian hospital La Fe" in collaboration with the service of Neurophysiology of the hospital. All patients undergoing sedation and mechanical ventilation (with an expected duration longer than 48h) and without any of the exclusion criteria detailed in the Methodology section will be included in the study. The intervention will consist of a muscular electrostimulation with the Super Pro Excel 70,UltratoneTM. The stimulation will be performed in 10 muscle groups (5 per side) following established protocols, at least 5 days a week. We will evaluate muscle strength by Medical Research Council scale, functional capacity by Barthel scale and Neurophaty Disability Scale, all clinical events will be collected and electrophysiologic, echographic and histologic parameters will be measured. The process of extubation will be performed following an established protocol, the duration will be collected as the same manner as ICU.

NCT ID: NCT02012933 No longer available - Clinical trials for Lambert-Eaton Myasthenic Syndrome (LEMS)

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Start date: n/a
Phase:
Study type: Expanded Access

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle junction. The major symptoms of LEMS are progressive muscle weakness. Many patients experience other symptoms like dry mouth or impotence. Congenital Myasthenia (CM) is an inherited disorder with similar affects and symptoms. 3,4-Diaminopyridine (DAP) is an experimental drug that has improved strength in some subjects with (LEMS). There are no other accepted treatments for LEMS and DAP has relatively few side effects.